Roundtable Discussion: Back-Translating Clinical Readouts into Discovery Workflows to Improve Model Relevance & Target Selection
- Interpreting clinical failures and efficacy ceilings in HS, AD and psoriasis, revealing which preclinical assumptions did or did not translate, to refine future target validation strategies
- Connecting patient pathology with animal, in vitro and tissuebased models, clarifying what each model truly represents, to avoid overinterpreting contrived systems
- Applying learnings from IL-17, IL-23, TNF, IL-1, JAK and OX40L programs, identifying pathway-specific translational gaps, to prioritise more clinically relevant discovery work